알츠하이머 치료제 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the alzheimer's therapeutics market size is projected to expand from USD 6.92 billion in 2025 and USD 7.48 billion in 2026 to USD 11.06 billion by 2031, registering a CAGR of 8.12% between 2026 to 2031.

This report is Segmented by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists, and More), Treatment Type (Symptomatic Treatment and Disease Modifying Therapies), Route of Administration (Oral and More), Distribution Channel (Hospital Pharmacies and More), Patient Stage (Mild Dementia and More), End User (Hospitals and More), and Geography (North America and More). Forecasts are in Value (USD).

Global Alzheimer's Therapeutics Market Trends and Insights

Rising Alzheimer's Prevalence and Aging Population

Alzheimer's disease accounts for 60-80% of all dementia cases, and the burden is rising as populations age across both mature and emerging healthcare systems. A 2025 global burden analysis projected that Alzheimer's disease and other dementias could affect 191 million people by 2050, with especially strong growth across East Asia, South Asia, and sub-Saharan Africa. In the United States, all baby boomers will be aged 65 or older by 2030, which places the largest insured patient pool at a point of rising incidence while newer treatments are scaling. At the same time, more than 60% of current dementia cases are already located in lower- and middle-income countries, where diagnostic access and reimbursement remain much weaker. This means the disease burden ceiling is much higher than the revenue ceiling in the Alzheimer's therapeutics market. It also means companies that build lower-cost oral pathways or simpler blood-test-led access models can reach demand that IV-focused treatment models cannot serve efficiently.

Disease-Modifying Therapy Adoption Expands Treatable Patient Pool

Traditional regulatory progress for anti-amyloid therapies has created the first commercially viable disease-modification category in the Alzheimer's therapeutics market, after years of clinical disappointment. By early 2025, 80% of surveyed neurologists reported discussing anti-amyloid therapies with patients, and the average number of patients per prescribing neurologist had increased nearly 5-fold from the prior year. That shift shows that specialist adoption moved from caution to active clinical planning. It also creates a more familiar treatment pathway for future agents that will not need to start from a cold market. The Alzheimer care model is therefore moving toward earlier intervention, which expands the commercial value of diagnosed patients. In practical terms, the Alzheimer's therapeutics market can now grow through both new product entry and deeper physician willingness to treat eligible patients.

High Treatment and Monitoring Cost Limits Broad Access

The access problem in the Alzheimer's therapeutics market extends beyond drug price into the full cost of diagnosis, monitoring, and delivery. NICE rejected both leading anti-amyloid drugs for routine NHS use, and a separate capacity analysis estimated that GBP 14 billion (USD 18.8 billion) would be needed over 10 years to bring England to G7-average diagnostic readiness for treatment eligibility assessment. In the United States, CMS continues to tie Medicare reimbursement for anti-amyloid monoclonal antibodies to registry participation under its Coverage with Evidence Development framework. That requirement adds process and staffing burdens for providers that do not already operate high-resource dementia programs. The result is uneven access, where insured patients close to specialist centers can move much faster than the wider age-eligible population. Even with online pharmacies growing at 11.25% CAGR, that channel cannot remove the high-touch infrastructure burden attached to parenteral DMT care in the Alzheimer's therapeutics market.

Other drivers and restraints analyzed in the detailed report include:

1. Biomarker-Led Patient Identification Improves Therapy Eligibility
2. Hospital-Based Infusion and Monitoring Infrastructure Supports Premium Therapies
3. Safety Monitoring Burden and Adverse Event Risk Restrict Uptake

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cholinesterase inhibitors held 52.31% of the Alzheimer's therapeutics market share in 2025, reflecting long prescribing history, generic availability, and broad affordability. NMDA receptor antagonists represented the second-largest position because they remain a standard option in moderate and severe disease management. Amyloid immunotherapies still formed a smaller revenue base, but they have started to influence treatment mix more directly than before. Combination drugs are projected to grow at a 10.38% CAGR from 2026 to 2031, which is the fastest pace within this segmentation. The Alzheimer's therapeutics market still relies on mature symptomatic classes for revenue stability even as newer categories gain traction.

The 2026 development pipeline contained 20 active combination therapy trials, equal to 11% of all active trials, which shows how strongly developers are leaning into multi-mechanism strategies. Eisai's study of E2814 with concurrent lecanemab is the clearest example of this approach now in motion. Repurposed assets accounted for 35% of all pipeline agents in 2026, which widened the field beyond traditional neurology pharmacology. That breadth supports a larger search for value across tau, neuroinflammation, metabolism, and related pathways. Other classes contribute useful depth, but near-term revenue in the Alzheimer's therapeutics market remains concentrated in established symptomatic products and early commercial DMT adoption.

Symptomatic treatments held 62.24% of the market in 2025, while disease-modifying therapies are projected to expand at a 10.52% CAGR through 2031. This split shows that the Alzheimer's therapeutics market still depends on long-established prescriptions for current revenue generation. Cholinesterase inhibitors and NMDA antagonists retain wide reach in systems where DMT reimbursement is not yet mature. Disease-modifying therapies are rising faster because they shift care toward earlier intervention rather than symptom control alone. The Alzheimer's therapeutics market size for disease-modifying therapies is therefore set to expand faster than the overall sector as care pathways become more standardized.

Clinical adoption accelerated sharply in 2025 as neurologists became more willing to discuss anti-amyloid treatment with patients. That change matters because DMT eligibility is tied to early pathology and functional stage rather than late-stage symptom burden. Earlier identification can extend treatment duration and increase the value of each treated patient over time. Symptomatic therapies are therefore shifting into a complementary role instead of remaining the only realistic option in many treatment journeys. If maintenance dosing keeps moving closer to the home, the Alzheimer's therapeutics market should face fewer care setting barriers in disease modification.

Complete Report Scope:

• By Drug Class
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Amyloid Immunotherapies
  • Combination Therapies
  • Other Drug Classes
• By Type of Treatment
  • Symptomatic Treatment
  • Disease Modifying Therapies
• By Route of Administration
  • Oral
  • Injectable
  • Transdermal
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Patient Stage
  • Mild Cognitive Impairment
  • Mild Dementia
  • Moderate Dementia
  • Severe Dementia
• By End User
  • Hospitals
  • Memory Clinics
  • Home Care Settings
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.24% of the Alzheimer's therapeutics market share in 2025, making it the largest regional revenue base. The United States drove this position with 7.4 million people aged 65 and older living with Alzheimer's dementia in 2026, while national health and long-term care costs are projected at USD 409 billion. The region also benefits from broader insurance depth and a defined Medicare pathway for anti-amyloid antibodies under Coverage with Evidence Development. Canada and Mexico remain smaller opportunities because specialist access and reimbursement breadth are more limited. Europe presents a more divided picture because lecanemab secured European Commission approval in 2025 while donanemab faced a less favorable benefit-risk outcome in Europe.

Asia-Pacific is projected to grow at an 11.15% CAGR from 2026 to 2031, which makes it the fastest regional growth zone in the Alzheimer's therapeutics market. Japan and China are positioned at the front of this expansion because they already have clearer paths for early DMT commercialization. The region also benefits from the growing role of blood-based diagnostics, which can reduce dependence on scarce PET infrastructure. South Korea, India, and Australia remain earlier in adoption, yet each has room to expand through better specialist access and earlier patient identification. The Alzheimer's therapeutics market in Asia-Pacific can scale quickly once diagnosis, monitoring, and reimbursement begin to move in the same direction.

South America and the Middle East and Africa remain smaller revenue contributors in the Alzheimer's therapeutics market, and symptomatic oral treatments still account for most demand. Brazil and Argentina lead South American activity, while the GCC countries offer the strongest near-term potential within MEA because healthcare spending and specialist capacity are relatively stronger. More than 60% of global dementia cases already occur in lower- and middle-income countries, yet most DMT revenue still accrues in high-income healthcare systems. Affordable oral drugs, broader awareness programs, and simpler diagnostic pathways will therefore determine how much of the Alzheimer's therapeutics market can open in these regions through 2031.

1. Abbvie
2. AC Immune SA
3. Alector, Inc.
4. Alzheon, Inc.
5. Anavex Life Sciences Corp.
6. Biogen
7. Denali Therapeutics
8. Eisai
9. Eli Lilly and Company
10. Roche
11. Grifols
12. H. Lundbeck
13. Johnson & Johnson
14. Merck
15. Novartis
16. Novo Nordisk
17. Otsuka
18. Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Alzheimer's Prevalence and Aging Population
  • 4.2.2 Disease Modifying Therapy Adoption Expands Treatable Patient Pool
  • 4.2.3 Biomarker Led Patient Identification Improves Therapy Eligibility
  • 4.2.4 Hospital Based Infusion and Monitoring Infrastructure Supports Premium Therapies
  • 4.2.5 Payer and Registry Pathways Are Normalizing Real World Evidence Based Access
  • 4.2.6 Repurposed Metabolic and Neuroprotective Assets Broaden the Pipeline
• 4.3 Market Restraints
  • 4.3.1 High Treatment and Monitoring Cost Limits Broad Access
  • 4.3.2 Safety Monitoring Burden and Adverse Event Risk Restrict Uptake
  • 4.3.3 Clinical Trial Failure and Attrition Increase Capital Risk
  • 4.3.4 Narrow Specialist Capacity Slows Diagnosis to Treatment Conversion
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Bargaining Power of Suppliers
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Threat of New Entrants
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Cholinesterase Inhibitors
  • 5.1.2 NMDA Receptor Antagonists
  • 5.1.3 Amyloid Immunotherapies
  • 5.1.4 Combination Therapies
  • 5.1.5 Other Drug Classes
• 5.2 By Type of Treatment
  • 5.2.1 Symptomatic Treatment
  • 5.2.2 Disease Modifying Therapies
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Injectable
  • 5.3.3 Transdermal
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
  • 5.4.4 Other Distribution Channels
• 5.5 By Patient Stage
  • 5.5.1 Mild Cognitive Impairment
  • 5.5.2 Mild Dementia
  • 5.5.3 Moderate Dementia
  • 5.5.4 Severe Dementia
• 5.6 By End User
  • 5.6.1 Hospitals
  • 5.6.2 Memory Clinics
  • 5.6.3 Home Care Settings
  • 5.6.4 Other End Users
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 AC Immune SA
  • 6.3.3 Alector, Inc.
  • 6.3.4 Alzheon, Inc.
  • 6.3.5 Anavex Life Sciences Corp.
  • 6.3.6 Biogen Inc.
  • 6.3.7 Denali Therapeutics Inc.
  • 6.3.8 Eisai Co., Ltd.
  • 6.3.9 Eli Lilly and Company
  • 6.3.10 F. Hoffmann-La Roche Ltd
  • 6.3.11 Grifols, S.A.
  • 6.3.12 H. Lundbeck A/S
  • 6.3.13 Johnson & Johnson
  • 6.3.14 Merck & Co., Inc.
  • 6.3.15 Novartis AG
  • 6.3.16 Novo Nordisk A/S
  • 6.3.17 Otsuka Pharmaceutical Co., Ltd.
  • 6.3.18 Takeda Pharmaceutical Company Limited

7 Market Opportunities & Future Outlook

• 7.1 White-Space and Unmet-Need Assessment